7567 Background: While mantle cell lymphoma (MCL) has historically been treated at the time of diagnosis, we recently reported a national cohort analysis which identified a subset of patients who can safely defer therapy (Cohen et. al, ASH 2015), validating previously reported single-center findings (Martin et al, JCO 2009). We conducted a multicenter analysis of MCL patients with additional clinical data to better describe the role of deferred therapy in MCL. Methods: Patients ≥ 18 years old who received initial treatment for newly diagnosed MCL between 1995-2015 at one of four academic sites were included. Deferred therapy was defined as receipt of first treatment > 90 days following diagnosis. We identified variables associated with receipt of deferred therapy and evaluated the impact of deferred therapy, demographic factors and MIPI components on progression-free (PFS) and overall survival (OS) in multivariable regression models. Results: Of 356 patients, 71 (20%) received deferred therapy with a median time to treatment for this group of 234 days. Among all patients, the median age at diagnosis was 62 years, 72% were male, 95% were stage III/IV, and 32% presented with B symptoms. Patients receiving deferred therapy were more likely to have an ECOG performance status of 0 (68% vs 49% p = 0.009), lack B symptoms (83% vs 65% p = 0.004) and have normal LDH levels at diagnosis (87% vs 57% p < 0.001). Patients receiving immediate treatment more commonly had bone marrow involvement (84% vs 71% p = 0.016) and splenomegaly (58% vs 41% p = 0.015). In multivariable analysis presence of complex karyotype (CK; ≥ 3 chromosomal abnormalities) was the only significant predictor of inferior OS (HR 3.17, 95% CI 1.69-5.95). Deferred therapy was not associated with differences in OS (HR 0.64: 95% CI 0.30-1.33, p = 0.228), and there was no significant difference in frequency of a CK between the deferred and immediate therapy groups (p = 0.3). Conclusions: This retrospective, multi-center cohort analysis validates prior findings that deferred therapy may be a safe option for a subgroup of MCL patients. Future studies are needed to better identify suitable candidates for deferred therapy.